Trinity Biotech Financials
| TRIB Stock | USD 0.72 0.01 1.37% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | 1.2813 |
|
|
The essential information of the day-to-day investment outlook for Trinity Biotech includes many different criteria found on its balance sheet. An individual investor should monitor Trinity Biotech's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Trinity Biotech.
Net Income |
|
Trinity | Select Account or Indicator | Build AI portfolio with Trinity Stock |
Please note, the presentation of Trinity Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Trinity Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Trinity Biotech's management manipulating its earnings.
Trinity Biotech Stock Summary
Trinity Biotech competes with Star Equity, Exagen, Burning Rock, OraSure Technologies, and ImmuCell. Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Bio operates under Pharmaceuticals And Biosciences classification in the United States and is traded on NASDAQ Exchange. It employs 477 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US8964383066 |
| CUSIP | 896438306 896438504 896438108 |
| Location | Ireland |
| Business Address | IDA Business Park, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.trinitybiotech.com |
| Phone | 353 1 276 9800 |
| Currency | USD - US Dollar |
Trinity Biotech Key Financial Ratios
| Return On Equity | -19.13 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.43) % | ||||
| Price To Sales | 0.22 X | ||||
| Revenue | 61.55 M |
Trinity Biotech Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 130.4M | 118.9M | 92.1M | 59.4M | 103.3M | 142.5M | |
| Other Current Liab | 9.6M | 7.9M | 9.1M | 8.9M | 21.5M | 22.6M | |
| Net Debt | 77.0M | 73.2M | 51.7M | 63.7M | 95.6M | 100.4M | |
| Retained Earnings | 10.6M | 12.6M | (26.7M) | (48.6M) | (79.1M) | (75.2M) | |
| Accounts Payable | 7.1M | 6.8M | 6.2M | 3.9M | 6.8M | 10.1M | |
| Cash | 27.3M | 25.9M | 6.6M | 3.7M | 5.2M | 4.9M | |
| Net Receivables | 24.6M | 15.7M | 13.4M | 13.4M | 14.6M | 17.2M | |
| Inventory | 30.2M | 29.1M | 22.5M | 19.9M | 19.4M | 26.0M | |
| Other Current Assets | 1.2M | 1.9M | 4.1M | 2.0M | 2.0M | 1.9M | |
| Total Liab | 132.6M | 119.2M | 94.3M | 83.4M | 138.5M | 145.4M | |
| Total Current Assets | 83.3M | 72.7M | 46.7M | 39.0M | 41.1M | 69.8M | |
| Short Term Debt | 5.1M | 85.3M | 1.9M | 1.9M | 2.5M | 2.4M | |
| Intangible Assets | 21.3M | 23.4M | 22.7M | 16.3M | 37.5M | 42.2M | |
| Long Term Debt | 82.0M | 83.9M | 58.0M | 54.7M | 87.8M | 46.5M | |
| Other Liab | 8.1M | 7.1M | 6.3M | 4.9M | 5.6M | 6.2M | |
| Other Assets | 33.0M | 29.5M | 18.1M | 4.3M | 5.0M | 4.7M | |
| Net Tangible Assets | 17.4M | (16.2M) | (22.6M) | (36.3M) | (32.7M) | (31.0M) |
Trinity Biotech Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Revenue | 102.0M | 93.0M | 74.8M | 56.8M | 61.6M | 79.2M | |
| Gross Profit | 48.6M | 38.1M | 22.0M | 19.5M | 21.4M | 35.1M | |
| Operating Income | 19.1M | 13.2M | (10.9M) | (27.0M) | (21.2M) | (20.1M) | |
| Ebit | 18.4M | 7.8M | (19.0M) | (25.9M) | (18.8M) | (17.8M) | |
| Ebitda | 21.5M | 10.6M | (16.7M) | (24.1M) | (16.9M) | (16.1M) | |
| Cost Of Revenue | 53.4M | 54.9M | 52.7M | 37.4M | 40.1M | 44.0M | |
| Income Before Tax | (6.6M) | 751K | (41.2M) | (36.9M) | (30.7M) | (29.2M) | |
| Net Income | (6.0M) | 875K | (41.0M) | (24.0M) | (31.8M) | (30.2M) | |
| Income Tax Expense | (620K) | (178K) | (192K) | (59K) | 486K | 431.9K | |
| Interest Expense | 6.8M | 7.1M | 24.7M | 10.1M | 12.0M | 12.6M | |
| Research Development | 5.1M | 4.5M | 4.1M | 4.4M | 4.5M | 5.0M | |
| Tax Provision | (182K) | (166K) | (192K) | (59K) | 486K | 510.3K | |
| Interest Income | 697K | 36K | 3K | 303K | 1.2M | 0.0 | |
| Net Interest Income | (4.9M) | (4.8M) | (24.4M) | (9.9M) | (13.1M) | (12.5M) |
Trinity Biotech Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (3.4M) | (4.4M) | (877K) | (971K) | (1.7M) | (1.8M) | |
| Change In Cash | 10.9M | (1.4M) | (19.3M) | (2.9M) | 1.5M | 1.5M | |
| Free Cash Flow | 13.6M | 4.5M | (6.9M) | (14.3M) | (14.3M) | (13.5M) | |
| Depreciation | 3.1M | 2.7M | 2.3M | 1.8M | 1.9M | 3.5M | |
| Other Non Cash Items | 22.3M | 8.9M | 37.9M | 11.4M | 17.7M | 18.6M | |
| Capital Expenditures | 10.2M | 8.7M | 6.0M | 803K | 10.1M | 10.0M | |
| Net Income | (6.4M) | 875K | (41.0M) | (24.0M) | (31.8M) | (30.2M) | |
| End Period Cash Flow | 27.3M | 25.9M | 6.6M | 3.7M | 5.2M | 4.9M | |
| Net Borrowings | (11.9M) | (3.5M) | 1.3M | (1.1M) | (969.3K) | (920.8K) | |
| Change To Netincome | 31.0M | 30.4M | 27.4M | 12.8M | 14.7M | 14.0M | |
| Investments | (10.2M) | (8.7M) | (6.0M) | 24.8M | (23.0M) | (21.8M) |
Trinity Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Trinity Biotech's current stock value. Our valuation model uses many indicators to compare Trinity Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Trinity Biotech competition to find correlations between indicators driving Trinity Biotech's intrinsic value. More Info.Trinity Biotech plc is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At present, Trinity Biotech's Return On Equity is projected to slightly grow based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Trinity Biotech's earnings, one of the primary drivers of an investment's value.Trinity Biotech plc Systematic Risk
Trinity Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Trinity Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Trinity Biotech plc correlated with the market. If Beta is less than 0 Trinity Biotech generally moves in the opposite direction as compared to the market. If Trinity Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Trinity Biotech plc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Trinity Biotech is generally in the same direction as the market. If Beta > 1 Trinity Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Trinity Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Trinity Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Trinity Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Trinity Biotech July 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Trinity Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Trinity Biotech plc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Trinity Biotech plc based on widely used predictive technical indicators. In general, we focus on analyzing Trinity Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Trinity Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.66 | |||
| Information Ratio | 0.0629 | |||
| Maximum Drawdown | 36.61 | |||
| Value At Risk | (6.56) | |||
| Potential Upside | 10.29 |
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |